Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 2Breast 2Lymphoid 1Dermatologic 1

Conditions

Ovarian Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Glucose × Gynecologic × Clear all
NCT03740165 2026-05-04

KEYLYNK-001

Merck Sharp & Dohme LLC

Phase 3 Completed
1,367 enrolled 29 charts
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00753740 2020-06-12

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Lumos Pharma

Phase 2 Withdrawn
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡